Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
JNCI Cancer Spectr. 2021 Jan 23;5(2). doi: 10.1093/jncics/pkab007. eCollection 2021 Apr.
Pediatric cancers are the leading cause of death by disease in children despite improved survival rates overall. The contribution of germline genetic susceptibility to pediatric cancer survivors has not been extensively characterized. We assessed the frequency of pathogenic or likely pathogenic (P/LP) variants in 5451 long-term pediatric cancer survivors from the Childhood Cancer Survivor Study.
Exome sequencing was conducted on germline DNA from 5451 pediatric cancer survivors (cases who survived ≥5 years from diagnosis; n = 5105 European) and 597 European cancer-free adults (controls). Analyses focused on comparing the frequency of rare P/LP variants in 237 cancer-susceptibility genes and a subset of 60 autosomal dominant high-to-moderate penetrance genes, for both case-case and case-control comparisons.
Of European cases, 4.1% harbored a P/LP variant in high-to-moderate penetrance autosomal dominant genes compared with 1.3% in controls (2-sided = 3 × 10). The highest frequency of P/LP variants was in genes typically associated with adult onset rather than pediatric cancers, including , , , , and . A statistically significant excess of P/LP variants, after correction for multiple tests, was detected in patients with central nervous system cancers (, , , ), Wilms tumor (, ), non-Hodgkin lymphoma (), and soft tissue sarcomas (, , , , ) compared with other pediatric cancers.
In long-term pediatric cancer survivors, we identified P/LP variants in cancer-susceptibility genes not previously associated with pediatric cancer as well as confirmed known associations. Further characterization of variants in these genes in pediatric cancer will be important to provide optimal genetic counseling for patients and their families.
尽管儿童癌症的总体生存率有所提高,但儿科癌症仍是导致儿童死亡的主要疾病原因。胚系遗传易感性对儿科癌症幸存者的影响尚未得到广泛描述。我们评估了来自儿童癌症幸存者研究的 5451 名长期儿科癌症幸存者中 5451 名个体的胚系遗传中致病性或可能致病性(P/LP)变异的频率。
对 5105 名欧洲裔儿科癌症幸存者(诊断后至少存活 5 年的病例)和 597 名欧洲无癌成年人(对照)的胚系 DNA 进行外显子组测序。分析侧重于比较 237 个癌症易感性基因和 60 个常染色体显性高至中度外显率基因的罕见 P/LP 变异在病例-病例和病例对照比较中的频率。
在欧洲裔病例中,与对照组的 1.3%相比,高至中度外显率常染色体显性基因中存在 P/LP 变异的比例为 4.1%(双侧=3×10)。P/LP 变异的最高频率发生在通常与成人发病而不是儿科癌症相关的基因中,包括、、、、和。在中枢神经系统癌症(、、、)、Wilms 瘤(、)、非霍奇金淋巴瘤()和软组织肉瘤(、、、、)患者中,校正多重检验后,检测到 P/LP 变异的频率明显高于其他儿科癌症患者。
在长期儿科癌症幸存者中,我们发现了先前与儿科癌症无关的癌症易感性基因中的 P/LP 变异,以及确认了已知的关联。对这些基因中的变异进行进一步的儿科癌症特征分析对于为患者及其家属提供最佳遗传咨询将是重要的。